Skip to main content
SpringerLink
Log in

Cost of antineoplastics leads to inequity of access

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. European Society for Medical Oncology

Reference

  • Cherny N, et al. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Annals of Oncology 27: 1423-43, No. 8, Aug 2016. Available from: URL: http://doi.org/10.1093/annonc/mdw213

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost of antineoplastics leads to inequity of access. PharmacoEcon Outcomes News 759, 12 (2016). https://doi.org/10.1007/s40274-016-3277-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3277-9

Search

Navigation